Biohaven Ltd., a global biopharmaceutical company based in New Haven, appointed technology investor John Yetimoglu to its Board of Directors as the company expands its use of AI in drug development.
Yetimoglu is Founder and Chief Investment Officer of Infinitum, an investment firm specializing in semiconductors, videogaming, and next-generation AI application platforms. He serves on the board of Groq, a leader in AI inference computing, where he was an early investor through the company's $20 billion transaction with NVIDIA in December 2025. Earlier in his career, Yetimoglu was an analyst at Morgan Stanley covering the technology and biotechnology sectors, and holds a bachelor's degree in economics from Columbia University.
The appointment reflects Biohaven's conviction that breakthroughs in medicine will increasingly be driven by the convergence of biology, data, and computation. As Biohaven expands its use of artificial intelligence, machine learning, and advanced computational methods across discovery, translational science, and clinical development, Yetimoglu's perspective on frontier technology is expected to strengthen the Board's strategic oversight in these areas.
Vlad Coric, M.D., Chief Executive Officer and Chairman of Biohaven, said, "John sits at the intersection of technology and life sciences at exactly the moment those worlds are coming together. His firsthand experience building and investing in category-defining AI companies gives our Board a rare, forward-looking vantage point as we integrate new computational approaches into how we discover and develop medicines for patients with serious diseases."
Biohaven focuses on discovering, developing, and commercializing therapies for people with debilitating diseases, with a pipeline spanning neuroscience, immunology, and other therapeutic areas.
"Biohaven has an extraordinary record of translating science into approved therapies, and the opportunity to apply modern AI and technology to drug development is only accelerating," said Yetimoglu. "I'm honored to join the Board, and to help Vlad and the company harness these tools in service of its mission to bring relief to patients."
